January 7, 2010

Clinical Trials: Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-Resistant Prostate Cancer

Sponsor and Collaborators
New York University School of Medicine
Novartis

Contact
Anna Ferrari, MD
212-731-5389
anna.ferrari@nyumc.org

Principal Investigator
Anna Ferrari, MD, New York University Cancer Institute

ClinicalTrials.gov Identifier
NCT00878436

Next post in Prostate Cancer Clinical Trials

Clinical Trials: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer